Nasdaq

Corbus Pharmaceuticals Presents Promising Phase 1 Dose-Escalation Study Findings for CRB ...

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
Nasdaq

Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO ...

Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...